The stock of Immune Design Corp (NASDAQ:IMDZ) is a huge mover today! About 102,715 shares traded hands. Immune Design Corp (NASDAQ:IMDZ) has declined 33.19% since March 9, 2016 and is downtrending. It has underperformed by 40.60% the S&P500.
The move comes after 7 months negative chart setup for the $169.88 million company. It was reported on Oct, 12 by Barchart.com. We have $6.39 PT which if reached, will make NASDAQ:IMDZ worth $16.99 million less.
Analysts await Immune Design Corp (NASDAQ:IMDZ) to report earnings on November, 10. They expect $-0.68 EPS, down 83.78% or $0.31 from last year’s $-0.37 per share. After $-0.71 actual EPS reported by Immune Design Corp for the previous quarter, Wall Street now forecasts -4.23% EPS growth.
Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage
Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, August 10 by Jefferies. The stock of Immune Design Corp (NASDAQ:IMDZ) has “Outperform” rating given on Tuesday, August 18 by Leerink Swann. As per Wednesday, September 9, the company rating was initiated by Jefferies.
According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.25 in Q2 2016. Its up 0.21, from 1.04 in 2016Q1. The ratio is positive, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.
Highbridge Ltd Limited Liability Company holds 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 26,452 shares. Blackrock Fund Advsrs holds 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 549,736 shares. Blackrock Institutional Tru Na has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Pnc Services Group has 76 shares for 0% of their US portfolio. Moreover, Blackrock Advsrs Limited has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 60,355 shares. National Bank & Trust Of New York Mellon holds 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 59,438 shares. Teacher Retirement Sys Of Texas, a Texas-based fund reported 1,129 shares. Tfs Capital Lc has 0.15% invested in the company for 102,685 shares. Amer Group, a New York-based fund reported 6,440 shares. Credit Suisse Ag reported 13,524 shares or 0% of all its holdings. Rs Invest Ltd Llc owns 1.23 million shares or 0.1% of their US portfolio. The Illinois-based Northern Trust Corp has invested 0% in Immune Design Corp (NASDAQ:IMDZ). Moreover, Cormorant Asset Mngmt Lc has 0.5% invested in Immune Design Corp (NASDAQ:IMDZ) for 432,990 shares. The Massachusetts-based Panagora Asset Mngmt has invested 0% in Immune Design Corp (NASDAQ:IMDZ). Walleye Trading Ltd owns 200 shares or 0% of their US portfolio.
Insider Transactions: Since July 15, 2016, the stock had 4 insider buys, and 0 sales for $10.26 million net activity. Shares for $5.00M were bought by COLUMN GROUP L P on Tuesday, September 20. $10,255 worth of shares were bought by Brady Stephen R on Friday, July 15. Svennilson Peter had bought 800,000 shares worth $5.00 million. COLEMAN LEWIS W also bought $250,000 worth of Immune Design Corp (NASDAQ:IMDZ) shares.
More recent Immune Design Corp (NASDAQ:IMDZ) news were published by: Gurufocus.com which released: “Immune Design Insider Buys Shares” on October 03, 2016. Also Streetinsider.com published the news titled: “Form 4 Immune Design Corp. For: Sep 20 Filed by: COLEMAN LEWIS W” on September 21, 2016. Globenewswire.com‘s news article titled: “Immune Design and Gritstone Oncology Announce Clinical Collaboration for …” with publication date: May 09, 2016 was also an interesting one.
IMDZ Company Profile
Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.